Is there any relationship between expressions of minor blood group antigens with HTLV-I infection?

Sadeghian, Mohammad Hadi; Keramati, Mohammad Reza; Ayatollahi, Hossein; Feizabadi, Atefeh Shirinzadeh; Tehranaian, Farahnaz; Shakibyee, Hossein

doi:10.1016/j.transci.2012.06.012

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1980, Poiesz discovered the type C retrovirus particle (Yoshida, ). HTLV‐1 is a health problem and is endemic in some regions, such as Japan, Africa, America, Australia, and Iran (Khorasan province, especially Neyshabour and Sabzevar; Figure ; Rafatpanah et al, ; Sadeghian et al, ). Approximately, 15–20 million HTLV‐1‐infected people have been identified globally (Naderi et al, ).…”

Section: Introductionmentioning

confidence: 99%

Current approaches for detection of human T‐lymphotropic virus Type 1: A systematic review

Fani

Rezayi

Meshkat

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Background Human T‐lymphotropic virus Type 1 (HTLV‐1) is a retrovirus that is endemic in some regions of the world. It is known to cause several diseases like adult T‐cell leukemia (ATL) and HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP). Serology and molecular methods have been used to detect this virus. Of these, enzyme‐linked immunosorbent assay (ELISA) is used as a primary screening method and this is usually followed by western blotting (WB) and polymerase chain reaction (PCR) methods as confirmatory tests. We conducted a systematic review of the different techniques used in the diagnosis of HTLV‐1 infection. Materials and Methods Our search was limited to original papers in the English language from 2010 to 2018 using several databases including Pubmed, Scopus, Google Scholar, Iranmedex, and Scientific Information Database. A manual search of references provided in the included papers was also performed. Results Of 101 electronically searched citations, 43 met the inclusion criteria. ELISA is commonly used for qualitative and screening detection, and WB and PCR techniques are used to confirm infection. Conclusion Among all the reported methods for detection of HTLV‐1, only serological and molecular tests are used as the most common technical assays for HTLV‐1. The ELISA assay, without a confirmatory test, has several limitations and affect the accuracy of the results. Owing to the prevalence of HTLV‐1 and limitations of the current detection methods, further evaluation of the accuracy of these methods is needed. There are new opportunities for applying novel technological advances in microfluidics, biosensors, and lab‐on‐a‐chip systems to perform HTLV‐1 diagnostics.

show abstract

Section: Introductionmentioning

confidence: 99%

Current approaches for detection of human T‐lymphotropic virus Type 1: A systematic review

Fani

Rezayi

Meshkat

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…Activation of JAK1 and JAK3 is also observed in HTLV-1 infected T cell lines or in uncultured leukemic cells from ATL patients [26]. The HTLV 1 is relatively common in the general population of our region (northeast Iran) [27] and it is very important that we find the contributing pathway in the pathogenesis of this virus. In the present study 20 ATL patients were investigated in addition to the 20 HTLV-1 carriers to analyze whether JAK2 is present; by using ARMS-PCR method.…”

Section: Discussionmentioning

confidence: 78%

JAK2 V617F Mutation in Adult T Cell Leukemia-Lymphoma

Ayatollahi

Sadeghian

Keramati

et al. 2015

Indian J Hematol Blood Transfus

Self Cite

View full text Add to dashboard Cite

Adult T cell Leukemia/lymphoma (ATL) is a mature T-cell neoplasm that has strong association with the human T-lymphotropic virus type 1 (HTLV-I) infection. This infection is endemic in our region (north eastern Iran). It has been highlighted that Janus Kinase family proteins and specially JAK2 mutations have a pivotal role in the development of many types of hematological malignancies and in particular myeloproliferative neoplasms. So far, the underlying molecular mechanisms leading to the ATL are not well understood. Therefore, in this study it was hypothesized that JAK2 (V617F) mutation may be present in samples from patients with ATL. This case control study was performed in north-eastern Iran. Using polymerase chain reaction, JAK2 (V617F) mutation was performed in 20 DNA samples from ATL patients and 20 HTLV-1 asymptomatic carriers (control group). The results of ATL subjects and the control group were compared by using SPSS software. In the case group 13 (65 %) and 7 patients (35 %) were male and female respectively, with the age range between 40 and 80 years. Only one patients has JAK2 mutation and this mutation was absent in 95 % of ATL patients as well as the HTLV-1 asymptomatic carriers. The results of our study demonstrated that JAK2 V617F mutation is not a common phenomenon in ATL. However, further studies are required to investigate the possible dysregulation of JAK signaling in ATL.

show abstract